The Restless Legs Syndrome (RLS) was originally described more than 300 years ago by Sir Thomas Willis in 1672.¹ Later, Swedish Neurologist Karl Ekbom in the year 1944, detailed a disorder of the central nervous system (brain) which predisposes to the constant desire to move the limbs at rest and deprivation of sleep² Surprisingly, research in the last three centuries has not proven the nervous system etiology originally suspected in RLS.³ Significant research points to the fact that RLS possibly originates consequent to local paucity of iron in the brain . The brain iron deficiency theory of RLS remains contentious and is not universally acceptable. Recently a large body of medical information tries to label RLS to be a sensorimotor disorder (a disease of the nerves / parts of the brain which help in the perception of pain or any sensation  (sensory nervous system) or which control the muscles  (motor nervous system).   Recently, a large body of medical information advocates nervous system targeted drug treatments without proven evidence. In fact none of the presently recommended neuropharmacological interventions were originally invented for treating RLS. They were formulated for treating a different spectrum of nervous disorder ( Parkinson's disease of the,  Ali fame )and found their way in treating RLS against conflicting evidence . “Ropinirole”, the recently FDA approved dopamine agonist drug ( drugs which behave like "Dopamine" , a chemical in the brain ) was originally approved for the early treatment of Parkinson’s disease. Till today there are no controlled studies, which prove the long-term safety ( more than  2-3 years ) and efficacy of this drug in treating RLS. In many of the cited clinical research studies on Ropinirole , have the patient take the drug for only 4-12 weeks, which in no way proves of it long term safety and efficacy or the ability to cure RLS.  Dr Richard Bogan